FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
188 letters match. Newest first.
-
DrugsSV Labs Corporation
SV Labs released microbe-contaminated OTC drug products and lacked water, process and quality controls, FDA says.
High risk -
DrugsDarmerica, LLC
FDA warns Darmerica over manufacturing-quality violations and mislabeled drug ingredients, including retatrutide.
High risk -
DrugsCDL Services, Inc. DBA Technichem
FDA warned CDL Services (Technichem), an Anaheim OTC drug maker, that it released hand sanitizer and hand soap batches without testing.
High risk -
DrugsOwen Biosciences, Inc.
Owen Biosciences' over-the-counter benzoyl peroxide acne lotion had over 20 parts per million benzene and lacked release testing.
High risk -
DrugsCdymax India Pharma Private Limited
FDA warned Cdymax (India) Pharma that its Bangalore API plant had inadequate out-of-specification investigations and unvalidated test methods, making its APIs adulterated.
High risk -
DrugsSeema International
FDA warns Seema International over unclean API equipment, missing stability data, and quality-unit failures after inspection; APIs adulterated.
High risk -
DrugsDermaRite Industries, LLC
DermaRite failed CGMP and sold unapproved, misbranded OTC topical drugs, FDA says.
High risk -
DrugsApotex Inc.
FDA cited Apotex's Richmond Hill sterile plant for failed investigations and aseptic contamination risks, prompting recalls.
High risk -
DrugsScientific Protein Laboratories, LLC
FDA warns Scientific Protein Laboratories over manufacturing failures in animal-derived APIs, including equipment particles and inadequate investigations.
High risk -
DrugsKath Khemicals LLC
FDA: Kath Khemicals, an OTC hand soap maker in Macomb, MI, released drugs without finished-product or glycerin identity testing.
High risk -
DrugsThe Tranzonic Companies/Innocore Sales & Marketing Inc.
FDA says Innocore Sales & Marketing, an over-the-counter drug manufacturer, lacked finished-product, component, stability and quality-unit controls.
High risk -
DrugsFoshan Yiying Hygiene Products Co., Ltd.
Foshan Yiying, a Chinese OTC drug maker, lacked finished-product testing, stability data and process validation; FDA has blocked its imports.
High risk -
DrugsGuangxi Yulin Pharmaceutical Group Co. Ltd.
FDA warned Guangxi Yulin Pharmaceutical Group that its OTC drugs lacked release testing and had data integrity failures.
High risk -
DrugsHealth and Natural Beauty USA Corp.
FDA warns Health and Natural Beauty USA over CGMP failures and unapproved, misbranded SprinJene OTC toothpastes, including children’s products.
High risk -
DrugsCreative Essences, Inc.
FDA warns Creative Essences over OTC drug manufacturing failures and an unapproved antiseptic.
High risk -
DrugsDixon Investments Inc. dba ARI
FDA cites Dixon Investments (ARI) for manufacturing-rule and unapproved/misbranded OTC aerosol drug violations.
High risk -
DrugsPersōn & Covey, Inc.
FDA cites Persōn & Covey for CGMP failures at its Glendale, CA drug plant and for selling unapproved Xerac AC and Drysol.
High risk -
DrugsJanssen Vaccines Corp., A Johnson & Johnson Company
FDA warned Janssen Vaccines over inadequate investigations of stopper complaints and missed regulatory notifications for its injection drug.
Medium -
DrugsYangzhou Yulou Paper Products Co., Ltd.
FDA cited Yangzhou Yulou Paper Products for manufacturing violations after records showed its OTC sterile drugs lacked sterility assurance and testing.
High risk -
AnimalMeds For Vets, LLC
Meds For Vets compounded unapproved animal drugs from bulk substances and failed manufacturing quality rules, including sterility controls.
High risk -
DrugsAnhui Hanbon Daily Chemical Co., Ltd.
FDA warns Anhui Hanbon Daily Chemical over CGMP failures in OTC drugs, including use of an incorrect excipient and untested ingredients.
High risk -
DrugsEverlaan Organics, Inc. dba Maple Organics
FDA warns Maple Organics over OTC drug CGMP failures, unapproved new drugs, and misbranding.
High risk -
DrugsGussyup LLC dba Private Label Grooming
FDA found Gussyup LLC, a Henderson, Nevada OTC drug maker, lacking quality oversight and ingredient identity testing; company stopped drug production.
High risk -
DrugsOasis Medical, Inc.
FDA cites Oasis Medical for current good manufacturing practice violations in sterile ophthalmic drugs, including particulate contamination and unresolved sterility failures.
High risk -
DrugsKabana Skin Care LLC
Kabana Skin Care failed to test OTC drug ingredients and finished products, prompting a recall and halt of U.S. drug manufacturing.
High risk -
DrugsMacsen Drugs
FDA cites Macsen Drugs for releasing fire-exposed APIs and inadequate stability data at India plant.
High risk -
DrugsGlenmark Pharmaceuticals Limited
FDA warns Glenmark over unresolved dissolution failures and inadequate investigations at its Pithampur, India drug plant.
High risk -
DrugsNature’s Fusions LLC
FDA cited Nature's Fusions for over-the-counter hand sanitizer manufacturing with inadequate stability, component and finished-product testing, and water controls.
High risk -
DrugsXtreme Tools International, Inc.
FDA warned Xtreme Tools International after an inspection found manufacturing-rule failures for OTC topical drugs, including missing ingredient and batch testing.
High risk -
DrugsExela Pharma Sciences, LLC
Exela Pharma Sciences failed CGMP (current good manufacturing practice) for sterile injectable drugs, including invalidated sterility-media tests and inaccurate microbiology records.
High risk -
DrugsPushclean Technology Plastik Sanayi Ve Ticaret Ltd. Sirketi
FDA warns Turkish OTC drug wipe maker Pushclean over missing finished-product and component testing.
High risk -
DrugsKenil Healthcare Private Limited
FDA warns Kenil Healthcare over adulterated drugs from India due to cleaning, packaging, and quality failures.
High risk -
DrugsHorizon Tool Inc.
FDA warns Horizon Tool over manufacturing-rule violations for AllShield E2 Sanitizing Hand Soap.
High risk -
DrugsEvi Labs LLC
FDA warns Evi Labs over OTC drug manufacturing failures, including an antiperspirant lot above the aluminum chlorohydrate limit.
High risk -
DrugsZhejiang Easyclean Daily Chemical Co., Ltd
FDA warned Zhejiang Easyclean Daily Chemical that its OTC drugs lacked required testing and manufacturing controls.
High risk -
DrugsHuangshi Hygienic Material Medicine Co., Ltd.
Huangshi Hygienic Material Medicine released U.S. drugs without identity and strength testing and lacked stability data for labeled expiration dates.
High risk -
DrugsProduct Society LLC
FDA says Product Society LLC, an OTC drugmaker in North Hollywood, California, skipped identity testing for toxic DEG/EG and process validation.
High risk -
DrugsWuxi Medical Instrument Factory Co., Ltd.
FDA warns Wuxi Medical Instrument Factory over insanitary conditions and manufacturing failures for sterile drugs.
High risk -
BiologicsSkye Biologics Holdings LLC
FDA warns Skye Biologics its umbilical cord-derived BioECM products are unapproved drugs and unlicensed biologics, made with serious manufacturing (CGMP) failures.
High risk -
DrugsMentha & Allied Products Private Ltd.
FDA warns Mentha & Allied Products of CGMP failures that leave its APIs adulterated.
High risk -
DrugsShantou S.E.Z. Baojie Industry Co., Ltd.
FDA warns Shantou S.E.Z. Baojie Industry over inadequate CGMP and component testing for OTC drug products, leading to Import Alert 66-40.
High risk -
DrugsTaizhou Jingshang Cosmetics Technology Co., Ltd.
FDA warns Taizhou Jingshang Cosmetics Technology over current good manufacturing practice failures in over-the-counter drugs, including missing identity tests for high-risk ingredients.
High risk -
DrugsBioAsia Worldwide Sdn Bhd
FDA warned BioAsia Worldwide over current good manufacturing practice violations for OTC drugs.
High risk -
DrugsCosco International, Inc.
FDA warned Cosco International over nonprescription drug manufacturing failures and unapproved drug products.
High risk -
DrugsDyno Manufacturing, Inc.
Dyno Manufacturing’s OTC hand sanitizer and antibacterial soap drugs lacked raw-material identity testing and other required manufacturing controls.
High risk -
DrugsPMS4PMS, LLC
FDA warns PMS4PMS of Clarence, NY, over CGMP failures and an unapproved menstrual cramp relief cream.
High risk -
DrugsYangzhou Sion Commodity Co., Ltd.
FDA warned Yangzhou Sion Commodity over drug manufacturing failures, including untested high-risk ingredients and unreliable lab records.
High risk -
DrugsAspen Biopharma Labs Private Limited
FDA warns Aspen Biopharma Labs over current good manufacturing practice failures in active ingredient manufacturing after U.S. recall.
High risk -
DrugsHangzhou Glamcos Biotech Co., Ltd.
Hangzhou Glamcos Biotech’s OTC antibacterial wipes had CGMP violations and were unapproved and misbranded, FDA says.
High risk -
DrugsNeva Global Grup Sanayi Ic Ve Dis Ticaret Anonim Sirketi
FDA warns Turkish OTC drug maker Neva Global over inadequate component testing, process validation, stability, and quality oversight.
High risk